LIGAND PHARMACEUTICALS INCORPORATED Business Acquisition, Pro Forma Net Income (Loss)
LIGAND PHARMACEUTICALS INCORPORATED (LGNXZ) reported Business Acquisition, Pro Forma Net Income (Loss) of $4.89 million for the 9-month period ending 2012-09-30, per its 10-Q filed 2012-11-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2012-11-14
- LIGAND PHARMACEUTICALS INCORPORATED business acquisition, pro forma net income (loss) for the quarter ending 2012-09-30 was -$4.09M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month |
|---|---|---|---|
| 2012-09-30 | -$4.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-14 | $4.89M 10-Q · filed 2012-11-14 | |
| 2012-06-30 | $8.97M 10-Q · filed 2012-08-08 |